02:17 PM EDT, 08/06/2025 (MT Newswires) -- The US Federal Trade Commission moved to prevent Edwards Lifesciences ( EW ) from acquiring JenaValve Technology, Edwards said on Wednesday.

"Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation," Edwards said in a statement. "The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR."

Edwards said it will continue seeking regulatory approval and expects a final determination by the end of Q1 next year.

The company said it now expects full-year 2025 adjusted earnings of $2.45 to $2.55 per share, versus $2.40 to $2.50 previously. Analysts polled by FactSet expect $2.49. The company also expects "minimal impact" on Q3 adjusted EPS guidance.

Price: 78.24, Change: -1.01, Percent Change: -1.27